药明康德近期披露,已与全球前20大制药企业全部建立长期合作,服务超过9000家临床前客户。这家中国CXO巨头构建的生态圈已完整覆盖从初创公司到行业巨头的所有玩家。与此同时,这个生态的核心子公司药明合联,刚刚以99%的溢价收购了竞争对手东曜药业。而东曜药业的主要股东维梧资本,正在国际法庭上与科兴生物进行着另一场关于现金分红的激烈诉讼。(见:维梧资本与科兴董事会二次“鏖战”。)01 精密的资本永动机...
Source Link药明康德近期披露,已与全球前20大制药企业全部建立长期合作,服务超过9000家临床前客户。这家中国CXO巨头构建的生态圈已完整覆盖从初创公司到行业巨头的所有玩家。与此同时,这个生态的核心子公司药明合联,刚刚以99%的溢价收购了竞争对手东曜药业。而东曜药业的主要股东维梧资本,正在国际法庭上与科兴生物进行着另一场关于现金分红的激烈诉讼。(见:维梧资本与科兴董事会二次“鏖战”。)01 精密的资本永动机...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.